Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells

Authors: Eric W Robbins, Emily A Travanty, Kui Yang, Kenneth A Iczkowski

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Dysregulated expression and splicing of cell adhesion marker CD44 is found in many types of cancer. In prostate cancer (PC) specifically, the standard isoform (CD44s) has been found to be downregulated compared with benign tissue whereas predominant variant isoform CD44v7-10 is upregulated. Mitogen-activated protein kinase pathways and paracrine calcitonin are two common factors linked to dysregulated expression and splicing of CD44 in cancer. Calcitonin has been found to increase proliferation and invasion in PC acting through the protein kinase A pathway.

Methods

In androgen-independent PC with known high CD44v7-10 expression, CD44 total and CD44v7-10 RNA or protein were assessed in response to exogenous and endogenous calcitonin and to inhibitors of protein kinase A, MEK, JNK, or p38 kinase. Benign cells and calcitonin receptor-negative PC cells were also tested.

Results

MEK or p38 but not JNK reduced CD44 total RNA by 40%–65% in cancer and benign cells. Inhibition of protein kinase A reduced CD44 total and v7-10 protein expression. In calcitonin receptor-positive cells only, calcitonin increased CD44 variant RNA and protein by 3 h and persisting to 48 h, apparently dependent on an uninhibited p38 pathway. Cells with constitutive CT expression showed an increase in CD44v7-10 mRNA but a decrease in CD44 total RNA.

Conclusion

The MEK pathway increases CD44 RNA, while calcitonin, acting through the protein kinase A and p38 pathway, facilitates variant splicing. These findings could be used in the formulation of therapeutic methods for PC targeting CD44 alternate splicing.
Appendix
Available only for authorised users
Literature
1.
Iczkowski KA, Pantazis CG, Collins J: The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol. 1997, 6: 119-129.
2.
Iczkowski KA, Bai S, Pantazis CG: Prostate cancer overexpresses CD44 variants 7–9 at the messenger RNA and protein level. Anticancer Res. 2003, 23: 3129-3140.PubMed
3.
Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest. 2004, 84: 894-907. 10.1038/labinvest.3700112. Editorial Comment: 811–813.CrossRefPubMed
4.
Iczkowski KA, Omara-Opyene AL, Shah GV: The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res. 2006, 26: 2863-2872.PubMed
5.
Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S: Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol. 1998, 160: 1562-1566. 10.1016/S0022-5347(01)62613-2.CrossRefPubMed
6.
Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV: Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res. 2005, 25: 2075-2083.PubMed
7.
Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, Lichtner RB, Herrlich P, Ponta H: A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993, 53: 1516-1521.PubMed
8.
Jothy S: CD44 and its partners in metastasis. Clin Exp Metastasis. 2003, 20: 195-201. 10.1023/A:1022931016285.CrossRefPubMed
9.
Vis AN, van Rhijn BW, Noordzij MA, Schroder FH, Kwast van der TH: Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002, 197: 148-154. 10.1002/path.1084.CrossRefPubMed
10.
Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, Kwast van der TH: Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol. 2000, 164: 2156-2161. 10.1016/S0022-5347(05)66989-3.CrossRefPubMed
11.
Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS: CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol. 2007, 31: 1119-1126.PubMed
12.
Lesley J, Kincade PW, Hyman R: Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol. 1993, 23: 1902-1909. 10.1002/eji.1830230826.CrossRefPubMed
13.
Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ, Mebust WK: Presence of calcitonin-like immunoreactivity in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate. 2007, 21: 87-97. 10.1002/pros.2990210202.CrossRef
14.
Chien J, Ren Y, Qing Wang Y, Bordelon W, Thompson E, Davis R, Rayford W, Shah G: Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol. 2001, 181: 69-79. 10.1016/S0303-7207(01)00530-5.CrossRefPubMed
15.
Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S, Mebust WK: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients. Endocrinology. 1994, 134: 596-602. 10.1210/en.134.2.596.PubMed
16.
Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, Iczkowski KA, Shah GV: Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer. 2005, 117: 551-560. 10.1002/ijc.21158.CrossRefPubMed
17.
Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG, Shah GV: Constitutive activation of stimulatory guanine nucleotide binding protein (Gsalpha-QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene. 1999, 18: 3376-3382. 10.1038/sj.onc.1202690.CrossRefPubMed
18.
Thomas S, Muralidharan A, Shah GV: Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol. 2007, 31: 1425-1437.PubMed
19.
Chien J, Shah GV: Role of stimulatory guanine nucleotide binding protein (Gsalpha) in proliferation of PC-3M prostate cancer cells. Int J Cancer. 2001, 91: 46-54. 10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0.CrossRefPubMed
20.
Marhaba R, Bourouba M, Zoller M: CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal. 2005, 17: 961-973. 10.1016/j.cellsig.2004.11.017.CrossRefPubMed
21.
Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16: 3074-3086. 10.1101/gad.242602.CrossRefPubMedPubMedCentral
22.
Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol. 2003, 4: 33-45. 10.1038/nrm1004.CrossRefPubMed
23.
Cheng C, Yaffe MB, Sharp PA: A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev. 2006, 20: 1715-1720. 10.1101/gad.1430906.CrossRefPubMedPubMedCentral
24.
Weg-Remers S, Ponta H, Herrlich P, Konig H: Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001, 20: 4194-4203. 10.1093/emboj/20.15.4194.CrossRefPubMedPubMedCentral
25.
Thomas S, Chigurupati S, Anbalagan M, Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol. 2006, 20: 1894-1911. 10.1210/me.2005-0284.CrossRefPubMed
26.
Forster-Horváth C, Bocsi J, Rásó E, Orbán TI, Olah E, Tímár J, Ladányi A: Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes. Eur J Immunol. 2001, 31: 600-608. 10.1002/1521-4141(200102)31:2<600::AID-IMMU600>3.0.CO;2-8.CrossRefPubMed
27.
Leemhuis J, Boutillier S, Schmidt G, Meyer DK: The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J Pharmacol Exp Ther. 2002, 300: 1000-1007. 10.1124/jpet.300.3.1000.CrossRefPubMed
28.
Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK: Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res. 2005, 11: 6065-6074. 10.1158/1078-0432.CCR-05-0009.CrossRefPubMed
29.
Davoodpour P, Landstrom M: 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem. 2005, 280: 14773-14779. 10.1074/jbc.M414470200.CrossRefPubMed
30.
Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF, Fang WG: ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 2004, 215: 239-247. 10.1016/j.canlet.2004.05.023.CrossRefPubMed
31.
Livak KL, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
32.
Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H: p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun. 2007, 353: 744-749. 10.1016/j.bbrc.2006.12.077.CrossRefPubMed
33.
Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R: Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol. 2006, 50: 1102-1109. 10.1016/j.eururo.2005.11.031.CrossRefPubMed
34.
Fujita Y, Kitagawa M, Nakamura S, Azuma K, Ishii G, Higashi M, Kishi H, Hiwasa T, Koda K, Nakajima N, Harigaya K: CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett. 2002, 528: 101-118. 10.1016/S0014-5793(02)03262-3.CrossRefPubMed
35.
Harrison GM, Davies G, Martin TA, Mason MD, Jiang WG: The influence of CD44v3–v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep. 2006, 15: 199-206.PubMed
36.
Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M: The p38 transduction pathway in prostatic neoplasia. J Pathol. 2006, 208: 401-407. 10.1002/path.1910.CrossRefPubMed
37.
Raught B, Gingras AC: eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol. 1999, 31: 43-57. 10.1016/S1357-2725(98)00131-9.CrossRefPubMed
38.
Cho SD, Ahn NS, Jung JW, Yang SR, Park JS, Lee YS, Jo EH, Hwang JW, Lii J, Kang KS: Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev. 2006, 15: 57-63. 10.1097/01.cej.0000195704.05246.fc.CrossRefPubMed
39.
Ster J, De Bock F, Guerineau NC, Janossy A, Barrere-Lemaire S, Bos JL, Bockaert J, Fagni L: Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent channels in cerebellar neurons. Proc Natl Acad Sci USA. 2007, 104: 2519-2524. 10.1073/pnas.0611031104.CrossRefPubMedPubMedCentral
Metadata
Title
MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells
Authors
Eric W Robbins
Emily A Travanty
Kui Yang
Kenneth A Iczkowski
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-260

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells

Research article

Nuclear hBD-1 accumulation in malignant salivary gland tumours

Research article

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

Research article

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

Research article

Association of common ATMvariants with familial breast cancer in a South American population

Research article

The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits